[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

May 2020, Vol 6, No. 5, Pages 608-792

Original Investigation

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial

Abstract Full Text
open access
JAMA Oncol. 2020;6(5):650-659. doi:10.1001/jamaoncol.2020.0147

This randomized clinical trial assesses whether treatment with stereotactic ablative radiotherapy vs observation improves oncologic outcomes in men with recurrent hormone-sensitive oligometastatic prostate cancer.

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial

Abstract Full Text
open access has audio
JAMA Oncol. 2020;6(5):661-674. doi:10.1001/jamaoncol.2020.0237

This randomized clinical trial compares durvalumab, with or without tremelimumab, with chemotherapy as a first-line treatment for metastatic non–small cell lung cancer.

Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial

Abstract Full Text
JAMA Oncol. 2020;6(5):676-684. doi:10.1001/jamaoncol.2019.6650

This analysis of data from an ongoing open-label adaptively randomized phase 2 platform trial examines the efficacy of adding pembrolizumab to standard neoadjuvant chemotherapy in patients with early-stage, high-risk, ERBB2-negative breast cancer.

Global Retinoblastoma Presentation and Analysis by National Income Level

Abstract Full Text
open access
JAMA Oncol. 2020;6(5):685-695. doi:10.1001/jamaoncol.2019.6716

This cross-sectional analysis reports the retinoblastoma stage at diagnosis across the world during a single year, investigates associations between clinical variables and national income level, and investigates risk factors for advanced disease at diagnosis.

Immune Response Following Quadrivalent Human Papillomavirus Vaccination in Women After Hematopoietic Allogeneic Stem Cell Transplant: A Nonrandomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(5):696-705. doi:10.1001/jamaoncol.2019.6722

This nonrandomized clinical trial examines the safety and immunogenicity of the quadrivalent human papillomavirus vaccine in clinically stable women post–allogeneic transplant compared with female healthy volunteers.

Incidence and Mortality Risk Spectrum Across Aggressive Variants of Papillary Thyroid Carcinoma

Abstract Full Text
JAMA Oncol. 2020;6(5):706-713. doi:10.1001/jamaoncol.2019.6851

This cohort study uses data from multiple US registries to analyze incidence, clinicopathologic characteristics, and outcomes for aggressive variants of papillary thyroid carcinoma.

Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients

Abstract Full Text
JAMA Oncol. 2020;6(5):714-723. doi:10.1001/jamaoncol.2020.0001

This cohort study assesses whether circulating microRNA profiles could be used as biomarkers to improve the detection of lung cancer in symptomatic patients.

Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma

Abstract Full Text
JAMA Oncol. 2020;6(5):724-734. doi:10.1001/jamaoncol.2020.0197

This next-generation exome sequencing study investigates the frequency of pathogenic or likely pathogenic germline genetic variants in known cancer-susceptibility genes among patients with osteosarcoma.

Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer

Abstract Full Text
JAMA Oncol. 2020;6(5):735-743. doi:10.1001/jamaoncol.2020.0109

This secondary analysis examines the association of prostate-specific antigen levels before salvage radiotherapy and net benefit of long-term antiandrogen treatment added to salvage radiotherapy for men with recurrent prostate cancer after radical prostatectomy.

Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial

Abstract Full Text
online only
JAMA Oncol. 2020;6(5):e196828. doi:10.1001/jamaoncol.2019.6828

This phase 3 randomized clinical trial compares treatment with carboplatin plus pemetrexed followed by pemetrexed maintenance with docetaxel monotherapy for overall survival for elderly Japanese patients with advanced nonsquamous non–small cell lung cancer (NSCLC).

Brief Report

Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2020;6(5):744-748. doi:10.1001/jamaoncol.2020.0007

This secondary analysis of a randomized clinical trial assesses treatment outcomes in women with different biological types of breast cancer according to germline variant status of BRCA1/2 and non-BRCA1/2 breast cancer predisposition genes.

Review

An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(5):764-771. doi:10.1001/jamaoncol.2019.5963

This narrative review discusses the key studies that have established the frequency and types of germline mutations in pancreatic ductal adenocarcinoma and implications for family members, strategies for genetic counseling, and treatment options for individuals with known germline mutations.

JAMA Oncology Clinical Challenge

Painful Cutaneous Plaques on the Lower Legs in a Middle-aged Woman

Abstract Full Text
has active quiz
JAMA Oncol. 2020;6(5):772-773. doi:10.1001/jamaoncol.2019.6839

A middle-aged woman presented with a 7-month history of erythematous plaques on the lower legs and intermittent fever during the past 3 months. What is your diagnosis?

Viewpoint

Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China

Abstract Full Text
free access has active quiz
JAMA Oncol. 2020;6(5):631-632. doi:10.1001/jamaoncol.2020.1198

This Viewpoint describes infection prevention and control measures implemented in the care of patients with cancer during the COVID-19 outbreak in China.

Cancer Survivorship—A Call to Action

Abstract Full Text
JAMA Oncol. 2020;6(5):632-633. doi:10.1001/jamaoncol.2019.5969

This Viewpoint assesses the state of cancer survivorship care, discusses the association of chemotherapy with coronary artery disease, and calls readers to action.

A New Therapeutic Era for Metastatic Renal Cell Carcinoma: Call for a New Prognostic Model

Abstract Full Text
JAMA Oncol. 2020;6(5):633-634. doi:10.1001/jamaoncol.2019.6862

This Viewpoint explores the use of molecular predictors of therapeutic responsiveness in assessing risk for patients with metastatic renal cell carcinoma.

Changing the Course of Cancer Care With Greater Precision

Abstract Full Text
JAMA Oncol. 2020;6(5):634-636. doi:10.1001/jamaoncol.2019.6843

This Viewpoint discusses the concept of precision cancer care delivery that includes patients, clinicians, data, and manufacturers.

Editorial

JAMA Oncology—The Year in Review, 2019

Abstract Full Text
free access
JAMA Oncol. 2020;6(5):639-640. doi:10.1001/jamaoncol.2020.0134
Invited Commentary

Forging New Strategies in the Cure of Human Oligometastatic Cancer

Abstract Full Text
JAMA Oncol. 2020;6(5):659-660. doi:10.1001/jamaoncol.2020.0195

The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy

Abstract Full Text
JAMA Oncol. 2020;6(5):674-675. doi:10.1001/jamaoncol.2020.0264
JAMA Oncology Patient Page

Circulating Tumor DNA Testing—Liquid Biopsy of a Cancer

Abstract Full Text
free access
JAMA Oncol. 2020;6(5):792. doi:10.1001/jamaoncol.2020.0346

This Patient Page describes the use of circulating tumor DNA testing to detect cancer-associated genetic variations and guide treatment recommendations.

Cancer Care Chronicles

A Totem for Ataxic Medical Deontology

Abstract Full Text
JAMA Oncol. 2020;6(5):637-638. doi:10.1001/jamaoncol.2020.0267

In this essay, the author describes a magnifying glass, given to him by his mentor, that becomes for him the symbol of blocking out all distractions to view with focused intent the primary importance of the patient’s well-being in the practice of medicine.

Comment & Response

Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer

Abstract Full Text
JAMA Oncol. 2020;6(5):782. doi:10.1001/jamaoncol.2020.0059

Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(5):782-783. doi:10.1001/jamaoncol.2020.0062

Questionable Survival Benefit of Aspirin Use in Patients With Biliary Tract Cancer

Abstract Full Text
JAMA Oncol. 2020;6(5):783-784. doi:10.1001/jamaoncol.2020.0122

Questionable Survival Benefit of Aspirin Use in Patients With Biliary Tract Cancer—Reply

Abstract Full Text
JAMA Oncol. 2020;6(5):784. doi:10.1001/jamaoncol.2020.0125

Future Research Suggestions for Multigene Testing in Unselected Populations

Abstract Full Text
JAMA Oncol. 2020;6(5):785. doi:10.1001/jamaoncol.2020.0128

Future Research Suggestions for Multigene Testing in Unselected Populations—Reply

Abstract Full Text
JAMA Oncol. 2020;6(5):785-786. doi:10.1001/jamaoncol.2020.0131

Double Counting of Patients in Meta-analyses of Observational Studies

Abstract Full Text
JAMA Oncol. 2020;6(5):786-787. doi:10.1001/jamaoncol.2020.0167

Double Counting of Patients in Meta-analyses of Observational Studies—Reply

Abstract Full Text
JAMA Oncol. 2020;6(5):787-788. doi:10.1001/jamaoncol.2020.0173

Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk

Abstract Full Text
JAMA Oncol. 2020;6(5):788. doi:10.1001/jamaoncol.2020.0261

Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk—Reply

Abstract Full Text
JAMA Oncol. 2020;6(5):788-789. doi:10.1001/jamaoncol.2020.0270
Correction

Error in Coauthor’s Affiliation

Abstract Full Text
free access
JAMA Oncol. 2020;6(5):789. doi:10.1001/jamaoncol.2020.0741

Error in Figure

Abstract Full Text
free access
JAMA Oncol. 2020;6(5):789. doi:10.1001/jamaoncol.2020.0896

Error in Author’s Name

Abstract Full Text
free access
JAMA Oncol. 2020;6(5):789. doi:10.1001/jamaoncol.2020.1421

Omission in the Article Information

Abstract Full Text
free access
JAMA Oncol. 2020;6(5):789. doi:10.1001/jamaoncol.2020.1108
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2020;6(5):608. doi:10.1001/jamaoncol.2019.4221
Peer Reviewers List

JAMA Oncology Peer Reviewers in 2019

Abstract Full Text
free access online only
JAMA Oncol. 2020;6(5):e200100. doi:10.1001/jamaoncol.2020.0100
×